tiprankstipranks
Advertisement
Advertisement

EYPT Stock Latest News

EyePoint Sues Ocular Therapeutix Over Alleged Defamation
Company AnnouncementsEyePoint Sues Ocular Therapeutix Over Alleged Defamation
16d ago
8K
EYPT
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
PremiumCompany Announcements
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
20d ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
20d ago
EYPT
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
PremiumRatings
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
27d ago
EYPT
EyePoint price target raised to $35 from $31 at Citi
PremiumThe Fly
EyePoint price target raised to $35 from $31 at Citi
27d ago
EYPT
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
PremiumCompany AnnouncementsEyePoint Pharma Bets Big on DuraVu in Pivotal Push
30d ago
EYPT
EyePoint price target raised to $30 from $23 at H.C. Wainwright
Premium
The Fly
EyePoint price target raised to $30 from $23 at H.C. Wainwright
1M ago
EYPT
EyePoint price target raised to $29 from $27 at Chardan
Premium
The Fly
EyePoint price target raised to $29 from $27 at Chardan
1M ago
EYPT
EyePoint reports Q4 EPS (81c), consensus (75c)
PremiumThe Fly
EyePoint reports Q4 EPS (81c), consensus (75c)
1M ago
EYPT
EyePoint expects cash to fund operations into Q4 2027
PremiumThe Fly
EyePoint expects cash to fund operations into Q4 2027
1M ago
EYPT
EyePoint Starts Global Phase 3 Trials for DURAVYU
PremiumCompany Announcements
EyePoint Starts Global Phase 3 Trials for DURAVYU
1M ago
8K
EYPT
EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
PremiumThe Fly
EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
1M ago
EYPT
Is EYPT a Buy, Before Earnings?
PremiumPre-EarningsIs EYPT a Buy, Before Earnings?
1M ago
EYPT
EyePoint price target raised to $36 from $33 at Mizuho
Premium
The Fly
EyePoint price target raised to $36 from $33 at Mizuho
2M ago
EYPT
EyePoint appoints Campbell as Chief Commercial Officer
Premium
The Fly
EyePoint appoints Campbell as Chief Commercial Officer
2M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
2M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
3M ago
EYPT
EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target
PremiumRatings
EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target
3M ago
EYPT
EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU
PremiumThe Fly
EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU
3M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe FlyEyePoint reports inducement grants under NASDAQ listing rule
4M ago
EYPT
Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD
Premium
Ratings
Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD
4M ago
EYPT
Buy Recommendation for EyePoint Pharmaceuticals: Strategic Positioning and Promising Wet AMD Therapy
Premium
Ratings
Buy Recommendation for EyePoint Pharmaceuticals: Strategic Positioning and Promising Wet AMD Therapy
4M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >